Date of Award


Document Type


Degree Name

Master of Science (MS)

Legacy Department


Committee Member

Dr. Frank Alexis, Committee Chair

Committee Member

Dr. Daniel Whitehead

Committee Member

Dr. Jacqueline Kraveka


lioblastoma and neuroblastoma are both solid-form tumors. Glioblastomas primarily reside in the brain, while neuroblastomas are found in the sympathetic nervous system. Both glioblastoma and neuroblastoma re classified as orphan diseases, which affect less than 200,000 individuals a year. Over the course of 5 years, 40% of patients diagnosed with neuroblastomas and only 6% of patients diagnosed will glioblastomas will be living.73,74. Glioblastoma and neuroblastoma tumors possess a gene known as MGMT. MGMT is used by tumors as a DNA repair mechanism, which increases the likelihood these tumors will become resistant to traditional drug therapies.28,37 Other pathways, such as the BER pathway, also contribute to drug resistance in tumors and cause them to be especially difficult to treat.65 The traditional treatment options for patients with glioblastomas or neuroblastomas are chemotherapy, radiation or surgery resecting the tumor. 5,18 These treatment options are ineffective due to the tumors' ability to resist drug treatments28 and due to the complicated nature of the resection surgery.2,,15 Combinations of traditional treatments are also becoming more popular and now patients are being treated with surgery and then with alkylating agents like TMZ for the remaining cells left behind. The focus of this research is to treat tumor cells with TMZ and increase it's effectiveness through combination drug therapy. The goal of this research was to formulate a polymeric nanoparticle delivery system that could deliver a non-toxic drug that will aid in the increased effectiveness of Temozolomide. Two drugs were encapsulated in poly(lactic acid)-poly(ethylene glycol) nanoparticles. The first drug, O6-Benzylguanine methylates the O6 loci on MGMT, which inhibits the gene. The second drug, methyl methanesulfonate, which inhibits the ALKb protein that also aids in DNA repair. 75 Particle sizing was performed to demonstrate that drug could effectively be loaded ii into the nanoparticles. Nanoparticle uptake studies were also performed to demonstrate the particle's ability to enter the tumor cells. Nanoparticle toxicity studies, free drug studies, and drug loaded combination studies were also performed to determine the efficacy of the treatment.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.